May 2026 · PPT
Source: Nse
Consumer stocks · SME cap · NSE
Yash Optics & Lens Ltd. manufactures, trades, distributes, and supplies spectacle/optical lenses across India, offering single-vision to advanced progressive lenses with multiple coating solutions. It markets products under own brands like "Lustraa" and is an exclusive distributor for Pentax and Optovision lenses. The company is backward integrating with a lens casting facility in Vapi.
SMA20 +6.2% / mo · MACD − · sector -3.7pp vs Nifty 500 (3M)
Latest mapped FPI equity flow was not positive. View sector evidence
Adjusted completed-session prices, rebased to 100
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Revenue +36.5% · PAT +25.4% YoY
Price trend and sector-relative-strength timing.
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Financial-only signal; management claim evidence is not sufficient yet.
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Rev +36% YoY · PAT +25% YoY · margin expansion · +31% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹30.6 Cr | +36.5% | +30.9% |
| EBITDA | ₹9.6 Cr | NDF | +88.1% |
| Operating margin | 31.4% | NDF | +953 bps |
| PAT | ₹5.9 Cr | +25.4% | +90.1% |
| PAT margin | 19.4% | NDF | +603 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Updated 20/10/2026
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Trend is constructive — long-term uptrend intact. RSI 46.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
U-Score 34 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Top U-Score contributors and drags from the latest stored fundamentals.
Consumer franchises can deserve higher multiples, but only when growth quality supports them.
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
12 stored score snapshots. Latest stored move: +0 points.
Business-comparable peers in Consumer — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Growth engines, risks, management commitments and evidence-backed delivery
Yash Optics reports strong H2 FY26 performance with revenue up 29.1% YoY and PAT up 17.6% YoY. Full-year FY26 revenue grew 25.0% YoY to INR 539.9 Mn, but PAT declined 5.6% YoY to INR 90.5 Mn, with margin compression.
The company demonstrates robust revenue growth, particularly in H2 FY26, driven by manufacturing transformation and distribution expansion. While full-year PAT declined due to margin compression, the strategic backward integration in Vapi and strong H2 operational momentum suggest the core thesis of becoming a dominant optical solutions provider remains on track.
Latest issuer-disclosed distribution across 2 reported categories.
Vapi facility enables import substitution, captive supply (~20%), B2B sales, and scalable capacity up to 20,000 pairs/day, improving cost efficiency and supply-chain control.
Operates a pan-India offline distribution network across distributors, opticians, optical showrooms, and institutional customers under B2B and B2C models.
Exclusive India manufacturing & distribution rights for Pentax (HOYA) and Optovision (Rodenstock Group) provide high entry barriers and brand credibility.
Strategy to scale partnerships with large optical chains, online players, and multi-showroom networks to drive stable volume growth.
Started manufacturing facility in Vapi and commenced production in 2026. Current capacity of ~10,000 lens pairs per day, expandable to 20,000 pairs per day.
Mumbai facility has a production capacity of 2400+ pairs per day with 70% utilization.
By 2030, ~4.7B people will require vision correction; only ~50% of the need is met globally, leaving over ~2B underserved. India's eyewear market is projected to grow to ~₹1,483 billion by FY30.
~95% of spectacle lenses are imported, largely from China. Backward integration aligns with Aatmanirbhar Bharat & China+1 strategy, reducing import dependence.
Growing optical chains are driving consistent demand for locally manufactured lenses, with only 24-36% of eyewear demand currently through organized channels.
The disclaimer notes risks including 'competition' in the industry.
The disclaimer mentions risks related to 'technological implementation, changes and advancements'.
Exclusive distribution rights for Pentax and Optovision are key pillars; changes in these partnerships could impact business.
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Both YoY and QoQ comparisons are crucial. YoY captures annual growth trends and the impact of strategic shifts like backward integration. QoQ highlights sequential momentum, especially in H2 FY26, which shows significant operational improvement after full-year margin pressure.
Revenue from Operations increased 25.0% YoY to INR 5,399.0 Lacs in FY26.
Gross Profit Margin was 66.9% in FY26, compared to 65.8% in FY25.
EBITDA Margin was 27.3% in FY26, down from 29.1% in FY25.
PAT Margin was 16.8% in FY26, down from 22.2% in FY25.
Management aims to expand backward integration capacities and gain bigger market share YoY.
Focus on strengthening proprietary brands to improve margins and enhance retail presence.
Support growing online eyewear demand through fast turnaround manufacturing.
Expand in-store hospital counters to capture prescription-driven demand.
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Vapi Facility Utilization | Current capacity ~10,000 lens pairs/day, expandable to 20,000. | Ramp-up of utilization and contribution to overall revenue and margins from the Vapi facility. |
| PAT Margin Trend | FY26 PAT Margin at 16.8%, down from 22.2% in FY25. | Improvement in PAT margins, especially as backward integration benefits materialize and raw material costs are managed. |
| Debt/Equity Ratio | 0.05 in FY26, down from 0.16 in FY25. | Maintenance of a healthy debt/equity ratio, especially with ongoing capacity expansions. |
| Domestic Market Share (Lens Casting) | Estimated ~2% domestic share from Vapi facility. | Growth in domestic market share for lens casting, indicating successful import substitution and B2B sales. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 59th percentile of the scored universe and 63rd percentile within Consumer. Main check: results consistency is weak at 38/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
overall median 67 · Consumer: 63rd pctile, median 66 · SME: 77th pctile, median 64
2 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Latest exchange and company disclosures found within the past two years.
Source: Nse
Source: Nse
Source: Nse
Source: Nse
Source: Nse